Like many industries at the cutting edge of technology, the biotech industry demands exceptional leadership. That is why biotech CEOs are prioritising identifying and developing leadership talent at all levels within their organisation.
This creates a compelling talent challenge for the biotech industry as it balances operational requirements with the benefits of identifying and developing high potentials in the business. Many clients grapple with the headache of finding one solution that meets both the strategic needs of the organization and the motivational needs of today’s biotech workforce. Scarcity of talent is the most limiting factor for biotech growth.
Expected to be worth over $700 billion globally by 2025, the biotech sector is in explosive growth mode, Added to the challenge is the fact that the sector tends to create concentrated ‘communities’ such as the Boston biotech ‘ecosystem’. This leads to major – and smaller – players in the industries, competing for the same talent pool, or facing additional relocation costs for top talent.
Norman Broadbent plc (LON:NBB) is a leading Professional Services firm offering five interrelated Talent Acquisition & Advisory Services: Board & Leadership/Executive Search, Senior Interim Management, Research & Insight, Leadership Consulting & Assessment, and executive level Recruitment solutions.